Alvotech (ALVO) Resumen de Acciones
Alvotech, a través de sus filiales, desarrolla y fabrica medicamentos biosimilares para pacientes de todo el mundo. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 5/6 |
| Crecimiento futuro | 5/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 1/6 |
| Dividendos | 0/6 |
ALVO Community Fair Values
Create NarrativeSee what 31 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Alvotech
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$3.42 |
| Máximo en las últimas 52 semanas | US$11.85 |
| Mínimo de 52 semanas | US$3.03 |
| Beta | 0.21 |
| Cambio en 1 mes | 1.18% |
| Variación en 3 meses | -16.38% |
| Cambio de 1 año | -69.81% |
| Variación en 3 años | -58.14% |
| Variación en 5 años | -65.10% |
| Variación desde la OPV | -64.92% |
Noticias y actualizaciones recientes
Actualización de narrativa • May 19
ALVO: 2026 Revenue Guidance And Pipeline Execution Will Drive Future Upside
Analysts have trimmed their price targets on Alvotech by $1 to $4. This reflects updated views on the company’s growth, profitability, discount rate, and future P/E assumptions.
Actualización de narrativa • Apr 29
ALVO: Biosimilar Pipeline And Patent Resolutions Will Support Future Upside
Analysts have reduced their average price target on Alvotech to $46.50, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margins and future P/E following recent target cuts from several major banks. Analyst Commentary Recent Street research on Alvotech has centered on recalibrated price targets, with several banks updating their models for valuation drivers such as revenue growth assumptions, margin profiles and target P/E multiples.Actualización de narrativa • Apr 15
ALVO: Biosimilar Pipeline And Partnerships Will Shape Future Upside Potential
Analysts have reduced their price targets on Alvotech, with the consolidated fair value estimate moving from $5.00 to $4.00 as they factor in more moderate revenue growth, lower profit margin assumptions, a higher discount rate, and a higher future P/E multiple. Analyst Commentary Bearish analysts are aligning around a lower fair value for Alvotech, with recent price target revisions pointing to a more cautious stance on the stock.Seeking Alpha • Apr 10
Alvotech: Improving Fundamentals Signal A Potential Bottom For This Biosimilar Player
Summary Alvotech is rated a speculative buy with a $4 price target, implying over 12% upside from current levels. ALVO posted double-digit revenue growth and positive GAAP profitability in FY 2025, but remains reliant on debt and minimal operating cash flow. 2026 catalysts include FDA approvals for key biosimilars and continued commercialization, with Selarsdi and AVT02 as major growth levers. Risks center on regulatory delays and high leverage (net debt/aEBITDA 9.3x), which could cap valuation and trigger corrections. Read the full article on Seeking AlphaRecent updates
Actualización de narrativa • May 19
ALVO: 2026 Revenue Guidance And Pipeline Execution Will Drive Future Upside
Analysts have trimmed their price targets on Alvotech by $1 to $4. This reflects updated views on the company’s growth, profitability, discount rate, and future P/E assumptions.Actualización de narrativa • Apr 29
ALVO: Biosimilar Pipeline And Patent Resolutions Will Support Future Upside
Analysts have reduced their average price target on Alvotech to $46.50, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margins and future P/E following recent target cuts from several major banks. Analyst Commentary Recent Street research on Alvotech has centered on recalibrated price targets, with several banks updating their models for valuation drivers such as revenue growth assumptions, margin profiles and target P/E multiples.Actualización de narrativa • Apr 15
ALVO: Biosimilar Pipeline And Partnerships Will Shape Future Upside Potential
Analysts have reduced their price targets on Alvotech, with the consolidated fair value estimate moving from $5.00 to $4.00 as they factor in more moderate revenue growth, lower profit margin assumptions, a higher discount rate, and a higher future P/E multiple. Analyst Commentary Bearish analysts are aligning around a lower fair value for Alvotech, with recent price target revisions pointing to a more cautious stance on the stock.Seeking Alpha • Apr 10
Alvotech: Improving Fundamentals Signal A Potential Bottom For This Biosimilar Player
Summary Alvotech is rated a speculative buy with a $4 price target, implying over 12% upside from current levels. ALVO posted double-digit revenue growth and positive GAAP profitability in FY 2025, but remains reliant on debt and minimal operating cash flow. 2026 catalysts include FDA approvals for key biosimilars and continued commercialization, with Selarsdi and AVT02 as major growth levers. Risks center on regulatory delays and high leverage (net debt/aEBITDA 9.3x), which could cap valuation and trigger corrections. Read the full article on Seeking Alpha
Actualización de narrativa • Mar 31
ALVO: Executing Biosimilar Pipeline And 2026 Revenue Plan Will Unlock Upside
Analysts have reset their view on Alvotech, trimming the average price target from about $22.17 to $14.00 as they factor in updated assumptions for growth, profitability and a higher future P/E, in line with recent target cuts from Deutsche Bank, Barclays and UBS. Analyst Commentary Recent Street research around the reset in the average price target to about $14.00 centers on how quickly Alvotech can execute on its pipeline and translate that into sustainable profitability, as well as what P/E multiple is appropriate given current visibility.Actualización de narrativa • Mar 17
ALVO: Biosimilar Pipeline Progress And Patent Resolutions Will Support Future Upside
Analysts have adjusted their price target for Alvotech to $64.74 per share. This reflects updated assumptions on discount rate, revenue growth, profit margins and future P/E, while keeping the overall valuation level unchanged.Actualización de narrativa • Mar 03
ALVO: Patent Resolution And Biosimilar Progress Will Support Future Upside
Analysts have updated their price target on Alvotech to $64.74 from $82.94, reflecting revised assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News Alvotech reported positive top line pharmacokinetic results for AVT80, its biosimilar candidate to Entyvio (vedolizumab), with the PK study meeting all primary endpoints in healthy adults, while biosimilarity has not yet been established by regulators.Actualización de narrativa • Feb 17
ALVO: Biosimilar Progress And New Partnerships Will Shape Balanced Risk Outlook
Analysts have raised their price target on Alvotech to $5.00. This change is supported by slightly higher assumptions for revenue growth, profit margin and future P/E.Actualización de narrativa • Feb 03
ALVO: Rebased UBS View And Patent Resolution Will Support Future Upside
Narrative Update on Alvotech Analysts have reduced their price expectations for Alvotech, with one recent update moving a target to US$10 from US$13, along with lower fair value estimates and more conservative assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Even with lower headline price targets, some bullish analysts still see room for upside in Alvotech.Actualización de narrativa • Jan 20
ALVO: FDA Letters And Facility Remediation Will Guide Balanced Risk Outlook
Narrative Update on Alvotech The updated analyst price targets for Alvotech, which now cluster around US$8 to US$10 compared with prior views near US$13 to US$14, reflect analysts factoring in recent FDA complete response letters tied to inspection findings at the Reykjavik facility, while still recognizing the unchanged US$5 fair value estimate and broadly similar growth and margin assumptions in the model. Analyst Commentary Recent Street research on Alvotech points to a more cautious tone, with price targets now centered in the US$8 to US$10 range and at least one rating move to Hold after the complete response letter for AVT05 and related inspection findings at the Reykjavik facility.Actualización de narrativa • Jan 05
ALVO: FDA Setbacks And Manufacturing Fixes Will Shape Balanced Risk Profile
Analysts have trimmed their fair value estimate for Alvotech from US$14.00 to US$5.00. This reflects lower price targets on the stock after recent FDA-related setbacks and manufacturing inspection concerns highlighted in recent research updates.Actualización de narrativa • Dec 17
ALVO: Resolution Of FDA Inspection Issues Will Unlock Biosimilar Launch Upside
Analysts have reduced their average price target for Alvotech from about $26.40 to roughly $22.17 per share, citing FDA inspection related uncertainties around key biosimilar launches, as well as a series of recent target cuts and rating downgrades, as justification for a lower, though still constructive, valuation framework. Analyst Commentary Recent Street research reflects a more cautious stance on Alvotech, with several firms cutting price targets and one moving to the sidelines following regulatory setbacks tied to the company’s biosimilar pipeline.Actualización de narrativa • Dec 03
ALVO: Regulatory Resolution Of Manufacturing Issues Will Restore Confidence And Future Upside
Analysts have trimmed their price targets on Alvotech, with cuts of roughly $3 to $6 per share. The reductions reflect increased perceived regulatory risk after recent FDA feedback on key biosimilar programs.Artículo de análisis • Nov 20
Statutory Earnings May Not Be The Best Way To Understand Alvotech's (NASDAQ:ALVO) True Position
Even though Alvotech ( NASDAQ:ALVO ) posted strong earnings recently, the stock hasn't reacted in a large way. We...Actualización de narrativa • Nov 19
ALVO: Regulatory Progress Will Drive Renewed Confidence Amid Recent Downgrade
Alvotech's fair value price target saw a significant increase from $16.10 to $26.40, as analysts revised their outlook based on recent research reports and updated fundamentals. Analyst Commentary Recent analyst reports on Alvotech reflect a mix of optimism about the company's long-term potential and caution regarding recent regulatory and operational setbacks.Artículo de análisis • Nov 09
Alvotech's (NASDAQ:ALVO) 31% Dip In Price Shows Sentiment Is Matching Revenues
Alvotech ( NASDAQ:ALVO ) shareholders that were waiting for something to happen have been dealt a blow with a 31% share...Artículo de análisis • Nov 06
Analysts Just Slashed Their Alvotech (NASDAQ:ALVO) EPS Numbers
Market forces rained on the parade of Alvotech ( NASDAQ:ALVO ) shareholders today, when the analysts downgraded their...Actualización de narrativa • Nov 05
ALVO: Facility Improvements Will Drive Recovery Despite Recent Regulatory Setbacks
Alvotech’s analyst price target has decreased from $17.50 to $16.10 per share. This change reflects analyst concerns over FDA feedback and the resulting downgrades after a recent inspection of the company’s manufacturing facility.Artículo de análisis • May 25
Alvotech (NASDAQ:ALVO) Held Back By Insufficient Growth Even After Shares Climb 29%
Those holding Alvotech ( NASDAQ:ALVO ) shares would be relieved that the share price has rebounded 29% in the last...Artículo de análisis • May 15
Alvotech's (NASDAQ:ALVO) Promising Earnings May Rest On Soft Foundations
Unsurprisingly, Alvotech's ( NASDAQ:ALVO ) stock price was strong on the back of its healthy earnings report. However...Nueva narrativa • May 05
Biosimilar Pipeline And R&D Capability Will Open New Markets
Upcoming biosimilar launches and strategic manufacturing expansions might drive substantial revenue and margin growth, leveraging lost biologic patents.Artículo de análisis • Apr 08
Benign Growth For Alvotech (NASDAQ:ALVO) Underpins Stock's 25% Plummet
Unfortunately for some shareholders, the Alvotech ( NASDAQ:ALVO ) share price has dived 25% in the last thirty days...Seeking Alpha • Nov 21
Alvotech's Position In The Coming Biosimilar Gold Rush
Summary Alvotech focuses on biosimilars, aiming to lower healthcare costs amid rising drug prices and regulatory pressure against price hikes. Alvotech's aggressive market expansion shows promise with significant revenue growth and strategic product rollouts, despite a leveraged balance sheet. A diverse pipeline targeting high-value biologics and recent regulatory milestones position Alvotech for significant market impact in the biosimilar sector. While facing risks like competition and partner dependency, Alvotech's strategic focus and operational scalability offer considerable growth potential for long-term investors. Read the full article on Seeking AlphaSeeking Alpha • Aug 26
Alvotech: Steady Progress Offers A Good Chance Of Upside
Summary Alvotech offers exposure to the biosimilar industry at a cheaper price compared to other generic drug manufacturers. The company has successfully commercialized two biosimilar drugs - Stelara and Humira - with more in the pipeline. The company announced Q2 earnings on August 16th, with record revenues of $235.6 million and quarterly EBITDA of $102 million. With revenues of $600 million to $800 million promised in 2025, Alvotech stock stands a good chance of realising upside in the second half of 2024. Read the full article on Seeking AlphaArtículo de análisis • May 28
Bullish: Analysts Just Made A Huge Upgrade To Their Alvotech (NASDAQ:ALVO) Forecasts
Celebrations may be in order for Alvotech ( NASDAQ:ALVO ) shareholders, with the analysts delivering a significant...Seeking Alpha • Apr 25
Alvotech: Consider Buying As Positive Q1 Earnings Release Likely
Summary Alvotech has received FDA approval for its biosimilar drugs Simlandi and Selarsdi, allowing the company to compete in the biosimilar market for Humira and Stelara. The company's stock price initially dropped after the FDA rejected Simlandi in 2023, but has since recovered. Alvotech's outlook for 2024 and 2025 is positive, with projected revenues of $300-$400 million and potential growth in the biosimilar market. Q1 2024 earnings will be announced on May 22 and have the potential to exceed Wall Street's expectations, in my view, setting the company on a long-term path to valuation growth, although significant headwinds remain in play. Read the full article on Seeking AlphaArtículo de análisis • Apr 03
Alvotech (NASDAQ:ALVO) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely
Alvotech ( NASDAQ:ALVO ) shares have had a horrible month, losing 28% after a relatively good period beforehand. The...Artículo de análisis • Mar 24
Alvotech (NASDAQ:ALVO) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
Alvotech ( NASDAQ:ALVO ) just released its latest yearly report and things are not looking great. It was not a great...Rentabilidad de los accionistas
| ALVO | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 4.3% | 3.1% | 1.2% |
| 1Y | -69.8% | 34.6% | 28.7% |
Rentabilidad vs. Industria: Los resultados de ALVO fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 34.6% el año pasado.
Rentabilidad vs. Mercado: ALVO obtuvo unos resultados inferiores a los del mercado US, que fueron del 28.7% el año pasado.
Volatilidad de los precios
| ALVO volatility | |
|---|---|
| ALVO Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: ALVO no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ALVO (9%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2013 | 1,279 | Lisa Graver | www.alvotech.com |
Alvotech, a través de sus filiales, desarrolla y fabrica medicamentos biosimilares para pacientes de todo el mundo. Ofrece productos biosimilares en las áreas terapéuticas de trastornos autoinmunes, oculares y óseos, así como cáncer. La empresa suministra AVT02, un biosimilar de Humira formulado con adalimumab de alta concentración y bajo volumen para tratar diversas afecciones inflamatorias, como artritis reumatoide, artritis psoriásica, enfermedad de Crohn, colitis ulcerosa con espondilitis anquilosante y otras indicaciones; AVT04, un biosimilar de Stelara para tratar diversas afecciones inflamatorias, como artritis psoriásica, enfermedad de Crohn, colitis ulcerosa, psoriasis en placas y otras indicaciones; AVT06, un biosimilar de Eylea para tratar diversas afecciones, como la degeneración macular neovascular asociada a la edad, el edema macular tras la oclusión de la vena retiniana, el edema macular diabético y la retinopatía diabética; y AVT03, un biosimilar de Xgeva y Prolia para tratar la prevención de fracturas óseas, la compresión de la médula espinal y la necesidad de radioterapia o cirugía ósea en pacientes con determinados tipos de cáncer, así como para prevenir la pérdida ósea y aumentar la masa ósea.
Resumen de fundamentos de Alvotech
| Estadísticas fundamentales de ALVO | |
|---|---|
| Capitalización bursátil | US$1.05b |
| Beneficios(TTM) | -US$80.73m |
| Ingresos (TTM) | US$562.04m |
1.9x
Ratio precio-ventas (PS)-13.3x
Ratio precio-beneficio (PE)¿Está ALVO sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ALVO | |
|---|---|
| Ingresos | US$562.04m |
| Coste de los ingresos | US$216.20m |
| Beneficio bruto | US$345.85m |
| Otros gastos | US$426.58m |
| Beneficios | -US$80.73m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
Aug 19, 2026
| Beneficios por acción (BPA) | -0.26 |
| Margen bruto | 61.53% |
| Margen de beneficio neto | -14.36% |
| Ratio deuda/patrimonio | -463.9% |
¿Cómo se ha desempeñado ALVO a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/26 02:18 |
| Precio de las acciones al final del día | 2026/05/26 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Alvotech está cubierta por 9 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Glen Santangelo | Barclays |
| Andrew Baum | Citigroup Inc |
| Peter Verdult | Citigroup Inc |